DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-529/S-004

Organon USA, Inc.
Attention: Ed Nellis
Senior Manager, Regulatory Affairs
56 Livingston Avenue
Roseland, NJ 07068

Dear Mr. Nellis:

Please refer to your supplemental new drug application dated May 6, 2008, received May 7, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for IMPLANON™ (etonogestrel implant) 68 mg.

We acknowledge receipt of your submissions dated November 6, 7, and 13, 2008.

This supplemental new drug application provides for changes to the physician insert in the (1) WARNINGS section regarding insertion and removal complications, (2) DOSAGE AND ADMINISTRATION section regarding the insertion site, and (3) INSTRUCTIONS FOR INSERTION AND REMOVAL section regarding the instructions for insertion and removal of the implant.

We have completed our review of this application, as amended, and the application is approved, effective on the date of this letter, for use as recommended in the enclosed labeling text.

Within 14 days of the date of this letter, submit content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format, as described at http://www.fda.gov/oc/datacouncil/spl.html that is identical in content to that submitted on November 13, 2007. Upon receipt and verification, we will transmit that version to the National Library of Medicine for public dissemination.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Charlene Williamson, Regulatory Project Manager, at (301) 796-1025.

Sincerely,

{See appended electronic signature page}

Scott Monroe, M.D.
Director
Division of Reproductive and Urologic Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Scott Monroe

2/19/2009 03:40:49 PM